Understanding Brensocatib's Mechanism and Safety in Bronchiectasis

In this segment of the HCPLive RX Review Special Report, Albert Rizzo, MD, and James Chalmers, MBChB, PhD, address safety considerations for brensocatib, marketed as Brinsupri, following its FDA approval in August 2025. Chalmers explains that both the phase 2 WILLOW trial and the large phase 3 ASPEN trial demonstrated a reassuring safety profile, with adverse events and serious events occurring at rates comparable to placebo. Importantly, despite targeting neutrophil activity, there was no observed increase in pneumonia or other infections—a critical finding given neutrophils’ role in host defense.